Cargando…
An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
BACKGROUND: Since the COVID-19 outbreak an unprecedented challenge for healthcare systems around the world has been placed. In Cuba, the first case of COVID-19 was reported on March 11. Elderly with multiple comorbidities have been the most risky population. Although most patients present a mild to...
Autores principales: | Saavedra, Danay, Añé-Kourí, Ana Laura, Sánchez, Naivy, Filgueira, Lázaro Manuel, Betancourt, Julio, Herrera, Carlos, Manso, Leniel, Chávez, Elibet, Caballero, Armando, Hidalgo, Carlos, Lorenzo, Geydi, Cepeda, Meylan, Valenzuela, Carmen, Ramos, Mayra, León, Kalet, Mazorra, Zaima, Crombet, Tania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666403/ https://www.ncbi.nlm.nih.gov/pubmed/33292350 http://dx.doi.org/10.1186/s12979-020-00207-8 |
Ejemplares similares
-
Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab
por: Caballero, Armando, et al.
Publicado: (2020) -
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases
por: Filgueira, Lázaro Manuel, et al.
Publicado: (2021) -
Itolizumab in Psoriasis
por: Srivastava, Ankita
Publicado: (2017) -
T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2017) -
Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2018)